Welcome to Crene Biotechnology!


Product :

LY2484595 Evacetrapib

LY2484595 Evacetrapib 1186486-62-3
Size Price Stock Quantity
Get Quotation Now Add to Cart Bulk Inquiry
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
Product name:LY2484595 Evacetrapib Purity:98% min
CAS NO:1186486-62-3 Solubility:10 mM in DMSO
Molecular Formula:C31H36F6N6O2 Package:Package according to customer requirements
Molecular Weight:638.6470 Storage:Store at -20℃
Quality control
Evacetrapib, also known as LY2484595, is a CETP inhibitor currently under development by Eli Lilly & Company. LY2484595 inhibits cholesterylester transfer protein, which transfers and thereby increases high-density lipoprotein and lowers low-density lipoprotein. It is thought that modifying lipoprotein levels modifies the risk of cardiovascular disease. The first CETP inhibitor, torcetrapib, was unsuccessful because it increased levels of the hormone aldosterone and increased blood pressure, which led to excess cardiac events when it was studied. Evacetrapib does not have the same effect. When studied in a small clinical trial in people with elevated LDL and low HDL, significant improvements were noted in their lipid profile. 
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Friendly link:

Copyright Copyright (C) 2018-2021Taizhou Crene Biotechnology Co., Ltd.

Address:Economic Developed Zone of Taizhou Zhejiang China.